
The phase III GAIA-CLL13 trial has provided evidence supporting the use of venetoclax-obinutuzumab, with or without ibrutinib, as a first-line treatment option for patients with chronic lymphocytic leukemia (CLL). CLL patients traditionally receive chemoimmunotherapy with rituximab and either fludarabine plus cyclophosphamide or bendamustine, based on their age. However, in the past decade, several new drugs have been approved for CLL, including ibrutinib, venetoclax, and obinutuzumab. The trial data indicates that the combination of venetoclax and obinutuzumab, with or without ibrutinib, can be effective in this setting.
Like
Save
Share